Digital The cliff was never the crisis: Pharma’s strategy problem The patent cliff isn't the problem. It's the symptom.
Sales & Marketing The hidden risks of biotech layoffs: Why cost-cutting trigge... Reducing your team without a strategic risk plan actually spikes corporate vulnerability more than it lowers burn rates.
R&D Sponsored From Alzheimer’s disease research to the real-world setting:... In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.
News Activist investor renews its criticism of Novavax Shah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a "destruction in shareholder value."
News Investor seeks sale of Novavax after poor COVID jab sales Investor Shah Capital has called on Novavax's board to put the company up for sale, citing a "litany of missteps" at the vaccine developer.
Market Access Which companies will last? Success begins with the basics Founding a new company is a high stakes business. Many leaders begin with an exciting, well-funded solution and then struggle to build a sustainable business over time.
News Tenax trounced by phase 3 heart failure readout Shares in Tenax 85% of their value after its drug for patients with pulmonary hypertension caused by a form of heart failure flunked a phase 3 trial.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
